Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine

Key Points The HIF inhibitor ACF suppresses TKI-insensitive CML stem cells. The FDA-approved drug ACF may represent a novel treatment to prevent CML relapse and, in combination with TKIs, improve remission.